• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Genotype Influences Mavacamten Responsiveness in Obstructive Hypertrophic Cardiomyopathy.

作者信息

Giudicessi John R, Alsidawi Said, Geske Jeffrey B, Newman Darrell B, Arruda-Olson Adelaide M, Bos J Martijn, Ommen Steve R, Ackerman Michael J

机构信息

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN; Department of Molecular Pharmacology and Experimental Therapeutics, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, MN.

Department of Cardiovascular Medicine, Mayo Clinic, Scottsdale, AZ.

出版信息

Mayo Clin Proc. 2024 Feb;99(2):341-343. doi: 10.1016/j.mayocp.2023.11.019.

DOI:10.1016/j.mayocp.2023.11.019
PMID:38309941
Abstract
摘要

相似文献

1
Genotype Influences Mavacamten Responsiveness in Obstructive Hypertrophic Cardiomyopathy.基因型影响梗阻性肥厚型心肌病对马伐卡坦的反应性。
Mayo Clin Proc. 2024 Feb;99(2):341-343. doi: 10.1016/j.mayocp.2023.11.019.
2
Pharmacogenetic Influences Over Mavacamten Pharmacokinetics: Considerations for the Treatment of Individuals With Hypertrophic Cardiomyopathy.药代遗传学对马伐卡坦药代动力学的影响：肥厚型心肌病患者治疗的考量
Circulation. 2024 Jun 4;149(23):1786-1788. doi: 10.1161/CIRCULATIONAHA.123.066916. Epub 2024 Jun 3.
3
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.马卡丹特治疗有症状梗阻性肥厚型心肌病（EXPLORER-HCM）的随机、双盲、安慰剂对照、3 期临床试验
Lancet. 2020 Sep 12;396(10253):759-769. doi: 10.1016/S0140-6736(20)31792-X. Epub 2020 Aug 29.
4
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.马卡丹特治疗有症状梗阻性肥厚型心肌病（EXPLORER-HCM）：一项随机、双盲、安慰剂对照、3 期临床试验的健康状况分析。
Lancet. 2021 Jun 26;397(10293):2467-2475. doi: 10.1016/S0140-6736(21)00763-7. Epub 2021 May 15.
5
Exploring New and Old Therapies for Obstructive Hypertrophic Cardiomyopathy: Mavacamten in Perspective.探索梗阻性肥厚型心肌病的新旧疗法：马伐卡坦的前景
Circulation. 2021 Mar 23;143(12):1181-1183. doi: 10.1161/CIRCULATIONAHA.120.051330. Epub 2021 Mar 22.
6
Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.马卡丹特对梗阻性肥厚型心肌病有症状患者超声心动图特征的影响。
J Am Coll Cardiol. 2021 Dec 21;78(25):2518-2532. doi: 10.1016/j.jacc.2021.09.1381.
7
Mavacamten (Camzyos) for obstructive hypertrophic cardiomyopathy.玛伐卡坦（卡姆佐）用于梗阻性肥厚型心肌病。
Med Lett Drugs Ther. 2022 Jun 13;64(1652):89-91.
8
Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy patients.马伐卡坦改善梗阻性肥厚型心肌病患者的症状。
Trends Pharmacol Sci. 2023 May;44(5):318-319. doi: 10.1016/j.tips.2023.02.005. Epub 2023 Mar 12.
9
Mavacamten (CAMZYOS) First-in-Class Small-Molecule Myosin Inhibitor for Treatment of Obstructive Hypertrophic Cardiomyopathy.马伐卡坦（CAMZYOS）：用于治疗梗阻性肥厚型心肌病的一流小分子肌球蛋白抑制剂。
Clin Nurse Spec. 2024;38(3):E3. doi: 10.1097/NUR.0000000000000822.
10
Mavacamten (CAMZYOS) First-in-Class Small-Molecule Myosin Inhibitor for Treatment of Obstructive Hypertrophic Cardiomyopathy.马伐卡坦（CAMZYOS）：用于治疗梗阻性肥厚型心肌病的首款小分子肌球蛋白抑制剂。
Clin Nurse Spec. 2024;38(3):119-121. doi: 10.1097/NUR.0000000000000821.

引用本文的文献

1
Enhancement of the Mayo Clinic HCM Genotype Predictor Score with Addition of Cardiac Magnetic Resonance Imaging.通过添加心脏磁共振成像来增强梅奥诊所肥厚型心肌病基因型预测评分
J Cardiovasc Transl Res. 2025 Jul 23. doi: 10.1007/s12265-025-10667-2.
2
Genetic insights into hypertrophic cardiomyopathy: pathogenesis, diagnosis, and therapeutic implications.肥厚型心肌病的遗传学见解：发病机制、诊断及治疗意义
J Cardiovasc Imaging. 2025 Jul 21;33(1):9. doi: 10.1186/s44348-025-00055-4.
3
Myosin inhibitors for treatment of hypertrophic cardiomyopathy.
用于治疗肥厚型心肌病的肌球蛋白抑制剂
Cochrane Database Syst Rev. 2025 Jun 23;6(6):CD016183. doi: 10.1002/14651858.CD016183.
4
Heterogeneous Dysregulation of Myosin Super-Relaxation and Energetics in Hypertrophic Cardiomyopathy.肥厚型心肌病中肌球蛋白超松弛和能量学的异质性失调
Circ Heart Fail. 2025 May 20:e012614. doi: 10.1161/CIRCHEARTFAILURE.124.012614.
5
Efficacy of Mavacamten in Reducing Cardiac Obstruction in an Elderly Patient with Hypertrophic Cardiomyopathy: A Case Study.马伐卡坦对一名老年肥厚型心肌病患者减轻心脏梗阻的疗效：一项病例研究
Am J Case Rep. 2025 Apr 18;26:e946956. doi: 10.12659/AJCR.946956.